SCHEDULE 13G/A: Goldman Sachs Reduces Stake in Larimar Therapeutics to 4.1%

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a beneficial ownership of 4.1% in Larimar Therapeutics, Inc. common stock as of March 31, 2025.

Summary

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Larimar Therapeutics, Inc.
• As of March 31, 2025, the reporting persons beneficially owned an aggregate of 2,600,210.85 shares of Larimar Therapeutics, Inc. common stock.
• This ownership represents 4.1% of the total class of securities.
• Both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC share voting and dispositive power over all 2,600,210.85 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in stake by a major institutional investor, which could be perceived as a lack of conviction or a strategic divestment, even if it's routine portfolio rebalancing.

Positives

• Goldman Sachs, a prominent financial institution, continues to hold a significant stake in Larimar Therapeutics, indicating ongoing interest in the company.

Negatives

• The reduction in beneficial ownership to 4.1% suggests that Goldman Sachs has decreased its stake in Larimar Therapeutics, which could be interpreted by the market as a reduction in conviction or a portfolio rebalancing.

Risks

• The primary risk stemming from this document is the potential negative market reaction to a major institutional investor reducing its stake, which could lead to selling pressure on Larimar Therapeutics' stock.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Larimar Therapeutics, Inc.'s business or the reporting entities' future investment intentions beyond the current ownership disclosure.

Management Comments

• The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing is a routine regulatory disclosure by a major institutional investor, Goldman Sachs, detailing its passive ownership stake in a biotechnology company, Larimar Therapeutics. Such adjustments in holdings are common as large funds rebalance portfolios or adjust positions based on market conditions or internal investment strategies. The reduction below 5% indicates a passive investment stance and no intent to influence management.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership and does not contain performance metrics or operational results for Larimar Therapeutics that would allow for direct comparison to industry standards or specific comparable companies/projects.
• The ownership percentage of 4.1% is below the 5% threshold that typically triggers initial 13G filings, suggesting a reduction from a previous higher stake. This is a common portfolio management activity for large investment firms like Goldman Sachs and does not inherently indicate a negative assessment of Larimar Therapeutics compared to its peers, but rather a change in investment allocation.

Stakeholder Impact

• Shareholders: May interpret the reduction in Goldman Sachs' stake as a negative signal, potentially leading to selling pressure or a re-evaluation of the stock.

Next Steps

• The document does not specify any future actions, events, or milestones for Larimar Therapeutics or the reporting entities beyond the regulatory filing requirements.

Key Dates

Recommendation

Keywords

Larimar Therapeutics, Goldman Sachs, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake